Constipation Drug Pipeline Analysis Report 2025
Description
Constipation is a common gastrointestinal condition characterized by infrequent, difficult, or painful bowel movements. It affects around 0.7%-79% of the global population. It has a higher prevalence in women than men. With better therapies and an increasing focus on improving patient outcomes, the constipation drug pipeline is expanding rapidly. Recent advancements include the development of novel constipation therapeutic products targeting gut motility and receptor modulation. Growing awareness, improved diagnostics, and patient-centric approaches are expected to drive significant growth in the constipation drug market in the coming years.
Report Coverage
The Constipation Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into constipation therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for constipation. The constipation report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The constipation pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with constipation treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to constipation.
Constipation Drug Pipeline Outlook
Constipation is a common digestive condition characterized by infrequent, difficult, or painful bowel movements. It occurs when the colon absorbs too much water from waste, leading to dry, hard stools. Factors such as a low-fiber diet, dehydration, lack of physical activity, and certain medications can contribute to constipation.
Constipation treatments include lifestyle changes like increasing fiber intake, hydration, and physical activity. Over-the-counter laxatives, stool softeners, and prescription medications targeting gut motility are also effective. Advanced treatments include prokinetic agents and novel therapeutic drugs, offering improved relief for chronic cases and enhancing patient outcomes.
Constipation Epidemiology
Constipation is a widespread gastrointestinal issue with varying prevalence across regions. In North America, approximately 16% of the population is affected, with higher rates in women and the elderly. The United Kingdom reports prevalence between 4% and 20%, leading to significant hospital admissions. In Germany, 6.8% of children experience constipation while in India, the prevalence ranges from 16.8% to 24.8%, highlighting the growing need for advanced constipation therapeutic products.
Constipation – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of constipation drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total constipation clinical trials.
Constipation – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the constipation pipeline analysis include small molecules, biologics, peptides, probiotics therapies, gene therapies. The constipation report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for constipation.
Constipation Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the constipation drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed constipation therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in constipation clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for constipation. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of constipation drug candidates.
Drug: Linaclotide
Linaclotide, sponsored by AbbVie, is currently being evaluated in a Phase III trial for pediatric patients aged 2 to 5 years with functional constipation (FC). This study aims to assess adverse events and symptom changes. Linaclotide is a guanylate cyclase-C (GC-C) agonist that increases intestinal fluid secretion, accelerates transit, and may reduce pain-sensing nerve activity in the intestine.
Drug: Naldemedine
Naldemedine, developed by Shionogi & Co., Ltd., is being tested in a Phase I/II trial to assess its pharmacokinetics, safety, and tolerability in pediatric patients on or about to start opioids. This oral medication functions by inhibiting opioid receptors in the gut, easing opioid-induced constipation (OIC) while maintaining pain control.
Reasons To Buy This Report
The Constipation Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for constipation. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into constipation collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Constipation – Pipeline Insight Report
Constipation Treatment Market Report and Forecast
Chronic Idiopathic Constipation (CIC) Epidemiology Forecast
Global Opioid Induced Constipation Market Report and Forecast
Global Clinical Trials Market
Report Coverage
The Constipation Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into constipation therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for constipation. The constipation report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The constipation pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with constipation treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to constipation.
Constipation Drug Pipeline Outlook
Constipation is a common digestive condition characterized by infrequent, difficult, or painful bowel movements. It occurs when the colon absorbs too much water from waste, leading to dry, hard stools. Factors such as a low-fiber diet, dehydration, lack of physical activity, and certain medications can contribute to constipation.
Constipation treatments include lifestyle changes like increasing fiber intake, hydration, and physical activity. Over-the-counter laxatives, stool softeners, and prescription medications targeting gut motility are also effective. Advanced treatments include prokinetic agents and novel therapeutic drugs, offering improved relief for chronic cases and enhancing patient outcomes.
Constipation Epidemiology
Constipation is a widespread gastrointestinal issue with varying prevalence across regions. In North America, approximately 16% of the population is affected, with higher rates in women and the elderly. The United Kingdom reports prevalence between 4% and 20%, leading to significant hospital admissions. In Germany, 6.8% of children experience constipation while in India, the prevalence ranges from 16.8% to 24.8%, highlighting the growing need for advanced constipation therapeutic products.
Constipation – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of constipation drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Biologics
- Peptides
- Probiotics Therapies
- Gene Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total constipation clinical trials.
Constipation – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the constipation pipeline analysis include small molecules, biologics, peptides, probiotics therapies, gene therapies. The constipation report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for constipation.
Constipation Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the constipation drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed constipation therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in constipation clinical trials:
- AbbVie
- Ardelyx
- BioGaia Pharma AB
- HK inno.N Corporation
- Shionogi
- Ironwood Pharmaceuticals, Inc.
- Braintree Laboratories
- Xian-Janssen Pharmaceutical Ltd.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for constipation. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of constipation drug candidates.
Drug: Linaclotide
Linaclotide, sponsored by AbbVie, is currently being evaluated in a Phase III trial for pediatric patients aged 2 to 5 years with functional constipation (FC). This study aims to assess adverse events and symptom changes. Linaclotide is a guanylate cyclase-C (GC-C) agonist that increases intestinal fluid secretion, accelerates transit, and may reduce pain-sensing nerve activity in the intestine.
Drug: Naldemedine
Naldemedine, developed by Shionogi & Co., Ltd., is being tested in a Phase I/II trial to assess its pharmacokinetics, safety, and tolerability in pediatric patients on or about to start opioids. This oral medication functions by inhibiting opioid receptors in the gut, easing opioid-induced constipation (OIC) while maintaining pain control.
Reasons To Buy This Report
The Constipation Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for constipation. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into constipation collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Constipation – Pipeline Insight Report
- Which companies/institutions are leading the constipation drug development?
- What is the efficacy and safety profile of constipation pipeline drugs?
- Which company is leading the constipation pipeline development activities?
- What is the current constipation commercial assessment?
- What are the opportunities and challenges present in the constipation drug pipeline landscape?
- What is the efficacy and safety profile of constipation pipeline drugs?
- Which company is conducting major trials for constipation drugs?
- Which companies/institutions are involved in constipation collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in constipation?
Constipation Treatment Market Report and Forecast
Chronic Idiopathic Constipation (CIC) Epidemiology Forecast
Global Opioid Induced Constipation Market Report and Forecast
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Constipation
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Constipation
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Constipation: Epidemiology Snapshot
- 5.1 Constipation Incidence by Key Markets
- 5.2 Constipation – Patients Seeking Treatment in Key Markets
- 6 Constipation: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Constipation: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Constipation, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Constipation Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Constipation Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Linaclotide
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Tenapanor
- 10.2.3 Other Drugs
- 11 Constipation Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Biological: Lactobacillus Gasseri BGP345A
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Naldemedine
- 11.2.3 Other Drugs
- 12 Constipation Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: IN-114199
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Constipation Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Constipation, Key Drug Pipeline Companies
- 14.1 AbbVie
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Ardelyx
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 BioGaia Pharma AB
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 HK inno.N Corporation
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Shionogi
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Ironwood Pharmaceuticals, Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Braintree Laboratories
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Xian-Janssen Pharmaceutical Ltd.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
